Summary

Eligibility
for people ages 18-75 (full criteria)
Location
at UC Davis UC Irvine
Dates
study started
completion around

Description

Summary

This study is designed to evaluate the efficacy of AMG 714 for the treatment of adult participants with vitiligo.

Official Title

Evaluation of AMG 714 for Vitiligo: A Phase 2a Randomized Double Blind Placebo Controlled Trial (ITN086AI)

Details

The primary objective of this trial is to determine the efficacy of interleukin-15 (IL-15) inhibition with AMG 714 at inducing facial repigmentation in vitiligo.

The secondary objectives are to:

-Evaluate the safety and tolerability of AMG 714 in vitiligo- -Determine the efficacy of IL-15 inhibition with AMG 714 at inducing total body skin repigmentation in vitiligo-

  • Assess the durability of the skin repigmentation achieved by AMG 714 in vitiligo, and
  • Evaluate the efficacy of AMG 714 followed by narrow band UVB (nbUVB) phototherapy.

Keywords

Vitiligo, efficacy, facial repigmentation, randomized placebo-controlled phase 2a trial, AMG 714, nbUVB phototherapy

Eligibility

Locations

  • University of California, Irvine: Department of Dermatology
    Irvine California 92697 United States
  • University of California Davis Health System: Department of Dermatology
    Sacramento California 95816 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Links
Immune Tolerance Network (ITN)
ID
NCT04338581
Phase
Phase 2 Vitiligo Research Study
Study Type
Interventional
Participants
Expecting 57 study participants
Last Updated